TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib
Hepatocellular carcinoma (HCC), as the major primary liver cancer, is one of the most prevalent malignant diseases with a high mortality rate worldwide. Prior studies have demonstrated that dihydroartemisinin (DHA), the semisynthetic derivative of artemisinin, possesses anti−HCC activity. The multik...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-06-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332220300524 |
id |
doaj-b1d253fb7fcc4eff93bf0933addb6cd7 |
---|---|
record_format |
Article |
spelling |
doaj-b1d253fb7fcc4eff93bf0933addb6cd72021-05-20T07:40:26ZengElsevierBiomedicine & Pharmacotherapy0753-33222020-06-01126109862TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenibChunying Hou0Dongqing Guo1Xue Yu2Shuyan Wang3Tianhua Liu4School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, ChinaSchool of Life Sciences, Beijing University of Chinese Medicine, Beijing, 100029, ChinaSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, ChinaSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, ChinaSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China; Corresponding author.Hepatocellular carcinoma (HCC), as the major primary liver cancer, is one of the most prevalent malignant diseases with a high mortality rate worldwide. Prior studies have demonstrated that dihydroartemisinin (DHA), the semisynthetic derivative of artemisinin, possesses anti−HCC activity. The multikinase inhibitor sorafenib has been approved for the treatment of HCC. However, the anti−HCC efficacy of DHA combined with sorafenib has not been reported. In this study, we confirmed the significantly enhanced anti−HCC efficacy of DHA in combination with sorafenib compared with that of each agent alone. Tandem Mass Tag (TMT) peptide labeling coupled with LC-MS/MS was used to quantify the proteins from the control, DHA, sorafenib, and DHA + sorafenib groups. In total, 532, 426, 628 differentially expressed proteins (fold change >1.20 or <0.83 and P-value <0.05) were determined by comparing DHA versus control, sorafenib versus control and DHA + sorafenib versus control groups, respectively. Moreover, optimized screening was performed, and 101 optimized differentially expressed proteins were identified. The results of functional analysis of the optimized differentially expressed proteins suggested that they were enriched in cell components such as membrane-bound vesicles, extracellular vesicles, and organelle lumens, and they were mainly involved in biological processes such as cellular component organization, response to stress, and response to chemicals; in addition, they were related to various molecular functions such as protein binding, chromatin binding and enzyme binding. KEGG pathway analysis showed that the optimized differentially expressed proteins were enriched in pyrimidine metabolism, RNA polymerase, base excision repair, and osteoclast differentiation. Protein-protein interaction (PPI) networks of some of the optimized upregulated proteins suggested that they might not only affect vitamin and fat digestion and absorption but may also be involved in tight junctions. In the PPI network, some of the optimized downregulated proteins were enriched in base excision repair, RNA polymerase, purine metabolism, pyrimidine metabolism and mucin type O-glycan biosynthesis. Overall, this research explored the anti−HCC efficacy of DHA combined with sorafenib by using the TMT-based quantitative proteomics technique and might facilitate the understanding of the related anti−HCC molecular mechanism.http://www.sciencedirect.com/science/article/pii/S0753332220300524Hepatocellular carcinomaDihydroartemisininSorafenibTMTProteomics |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Chunying Hou Dongqing Guo Xue Yu Shuyan Wang Tianhua Liu |
spellingShingle |
Chunying Hou Dongqing Guo Xue Yu Shuyan Wang Tianhua Liu TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib Biomedicine & Pharmacotherapy Hepatocellular carcinoma Dihydroartemisinin Sorafenib TMT Proteomics |
author_facet |
Chunying Hou Dongqing Guo Xue Yu Shuyan Wang Tianhua Liu |
author_sort |
Chunying Hou |
title |
TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib |
title_short |
TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib |
title_full |
TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib |
title_fullStr |
TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib |
title_full_unstemmed |
TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib |
title_sort |
tmt-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib |
publisher |
Elsevier |
series |
Biomedicine & Pharmacotherapy |
issn |
0753-3322 |
publishDate |
2020-06-01 |
description |
Hepatocellular carcinoma (HCC), as the major primary liver cancer, is one of the most prevalent malignant diseases with a high mortality rate worldwide. Prior studies have demonstrated that dihydroartemisinin (DHA), the semisynthetic derivative of artemisinin, possesses anti−HCC activity. The multikinase inhibitor sorafenib has been approved for the treatment of HCC. However, the anti−HCC efficacy of DHA combined with sorafenib has not been reported. In this study, we confirmed the significantly enhanced anti−HCC efficacy of DHA in combination with sorafenib compared with that of each agent alone. Tandem Mass Tag (TMT) peptide labeling coupled with LC-MS/MS was used to quantify the proteins from the control, DHA, sorafenib, and DHA + sorafenib groups. In total, 532, 426, 628 differentially expressed proteins (fold change >1.20 or <0.83 and P-value <0.05) were determined by comparing DHA versus control, sorafenib versus control and DHA + sorafenib versus control groups, respectively. Moreover, optimized screening was performed, and 101 optimized differentially expressed proteins were identified. The results of functional analysis of the optimized differentially expressed proteins suggested that they were enriched in cell components such as membrane-bound vesicles, extracellular vesicles, and organelle lumens, and they were mainly involved in biological processes such as cellular component organization, response to stress, and response to chemicals; in addition, they were related to various molecular functions such as protein binding, chromatin binding and enzyme binding. KEGG pathway analysis showed that the optimized differentially expressed proteins were enriched in pyrimidine metabolism, RNA polymerase, base excision repair, and osteoclast differentiation. Protein-protein interaction (PPI) networks of some of the optimized upregulated proteins suggested that they might not only affect vitamin and fat digestion and absorption but may also be involved in tight junctions. In the PPI network, some of the optimized downregulated proteins were enriched in base excision repair, RNA polymerase, purine metabolism, pyrimidine metabolism and mucin type O-glycan biosynthesis. Overall, this research explored the anti−HCC efficacy of DHA combined with sorafenib by using the TMT-based quantitative proteomics technique and might facilitate the understanding of the related anti−HCC molecular mechanism. |
topic |
Hepatocellular carcinoma Dihydroartemisinin Sorafenib TMT Proteomics |
url |
http://www.sciencedirect.com/science/article/pii/S0753332220300524 |
work_keys_str_mv |
AT chunyinghou tmtbasedproteomicsanalysisoftheantihepatocellularcarcinomaeffectofcombineddihydroartemisininandsorafenib AT dongqingguo tmtbasedproteomicsanalysisoftheantihepatocellularcarcinomaeffectofcombineddihydroartemisininandsorafenib AT xueyu tmtbasedproteomicsanalysisoftheantihepatocellularcarcinomaeffectofcombineddihydroartemisininandsorafenib AT shuyanwang tmtbasedproteomicsanalysisoftheantihepatocellularcarcinomaeffectofcombineddihydroartemisininandsorafenib AT tianhualiu tmtbasedproteomicsanalysisoftheantihepatocellularcarcinomaeffectofcombineddihydroartemisininandsorafenib |
_version_ |
1721435138682781696 |